A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC
Vandetanib, Docetaxel
NCT00312377, EudraCT2005-004749-32
Non-Small Cell Lung Cancer
Phase 3
Datasets and document are available as per Sanofi Policy and criteria
May 2017